healthcarereimagined

Let us begin with the Japanese dentist. Not a specific dentist. The concept. In Japan, you make an appointment, you see the dentist, you pay a modest fee that the national insurance has already negotiated, and you go home. The appointment was on time. The equipment was current. The dentist went to medical school without accumulating the debt load of a medium-sized house. This is not a utopia. Japan has its own healthcare problems, mostly involving an extremely old population and a hospital system that is at capacity. But the dentist was on time.

Now let us describe the British experience of the same dentist. There are not enough NHS dentists. This has been true for a decade and is getting worse. In 2023, 26% of people in the UK skipped dental care because of the cost, compared to just 6% in 2013. The people who wanted NHS dental appointments and could not get them because there were no appointments available had a choice: pay privately, which is expensive enough that a significant number of people did not do it, or fly to Turkey. They flew to Turkey. More than 1.2 million people from Europe visit Turkey annually for surgical procedures. Search volume for cosmetic surgery Turkey from UK users grew 500% between 2015 and 2023. Turkey’s health tourism revenue reached a record 10 billion dollars in 2024. The NHS then spent up to 20,000 pounds per patient managing the complications that some of them brought home. The NHS is paying for the sequel to a film it refused to produce.

This essay is about the global healthcare system, which is not a single thing but which has a very clear hierarchy of functioning. At the top are countries where healthcare works. At the bottom are countries where it demonstrably does not. And in the middle is a specific group of English-speaking countries that were once considered among the more enlightened models on earth, that made a series of structural decisions in the 1980s and 1990s, and that are now producing wait times, outcomes, and access failures that belong in a much lower tier than their GDP per capita would suggest. They planted the seeds thirty years ago. They are currently eating the harvest and calling it a crisis, which is what happens when you eat the harvest of seeds you planted and are surprised.

The Countries Where It Works. And the Specific Reason It Works There.

Japan’s healthcare system spends approximately 4,100 dollars per capita per year. Life expectancy is 84.6 years, the highest of any large economy. Infant mortality is 1.9 per 1,000 live births, among the lowest on earth. Out-of-pocket spending is 9% of total health expenditure. The system covers 100% of the population through a universal fee-schedule based insurance model. Administrative waste is kept to under 10% of total costs. Japan does not have a particularly simple system, it has multiple insurers, multiple payers, complex regional structures, but it has one thing that prevents complexity from becoming corruption: the government sets the fees. Every procedure has a nationally negotiated price. Nobody can charge more. Nobody can charge less. The market forces that would otherwise allow prices to detach from reality have been removed from the equation by design.

This is the thing that makes Japan’s model hard to copy and easy to explain. The price is the price. A hospital cannot charge more for an appendectomy because it is the only hospital in the region. A pharmaceutical company cannot charge 40 times more for a drug in Japan than in France because it needs to fund American marketing campaigns. The price is the price. The system has costs, mostly related to an ageing population stretching a fixed infrastructure, but the fundamental mechanism works because the fundamental mechanism is not permitted to be exploited.

Germany spends 12.7% of GDP on healthcare. Japan spends about 11%. The United States spends about 18%. Japan gets a life expectancy of 84.6 years. The US gets 76.4. Germany gets 81.1. These are not small differences. These are years of life per person that are simply not being lived in the country spending the most money. The US healthcare system is the most expensive in the world and produces outcomes that rank 69th globally. This is the same rank as countries with a fraction of the per capita spending. The graph of money versus outcomes for the United States looks like a child drew it.

Singapore is a slightly different model but produces a comparable result. It blends mandatory savings accounts, called MediSave, with government subsidies and a competitive private market. Life expectancy is 83.5 years. Patient satisfaction is 89%. Out-of-pocket spending averages 10% of total health costs, among the lowest for a high-income economy. Administrative waste is under 5%. Singapore ranks first for healthcare efficiency globally on multiple indices. The specific insight Singapore applied is that the government negotiates drug prices directly, which keeps medication costs low, and that the savings account mechanism means people have a personal financial stake in not overusing the system, without creating the American problem where fear of cost prevents people from using it at all. This balance is genuinely difficult to strike and Singapore mostly struck it.

South Korea, Taiwan, and the Netherlands produce similar results through similar philosophies: universal coverage, centrally negotiated prices, strong primary care as the first line, and administrative systems that are designed to serve the patient rather than to serve the administrative system. The Numbeo Healthcare Index for 2026 places Taiwan first, South Korea second, and the Netherlands third. The United States is not in the top 60. This is the country that spends the most money on healthcare, producing outcomes that rank 69th globally, which would be an extraordinary satirical invention if it were not a publicly verifiable fact.

The countries where healthcare works have a common feature. The price is controlled. Not by market forces, which left to their own devices in healthcare produce the American result. By governments that understood the information asymmetry problem, decided to address it rather than celebrate it, and built pricing mechanisms that prevent the extraction of maximum value from someone who is sick and has no alternative. This is not complicated. It required political will. The countries that applied it are, by outcome measurement, better places to have a body.

The English-Speaking Countries. A Separate Category of Avoidable Failure.

There is a specific phenomenon happening in the United Kingdom, Canada, Australia, and New Zealand that deserves its own section, because it is distinct from both the successful models described above and from the American catastrophe that gets most of the attention. These countries built functional universal healthcare systems in the mid-20th century. They built them well. They worked. And then, beginning in the 1980s and accelerating through the 1990s and 2000s, they made a series of structural decisions that have been slowly dismantling what they built while maintaining the name, the logo, and the political rhetoric.

Canada’s median wait time from referral by a general practitioner to specialist consultation to actual treatment in 2025 was 28.6 weeks, the second-longest ever recorded by the Fraser Institute in 30 years of tracking this data. That is seven months. For non-emergency treatment of conditions that are nonetheless affecting your quality of life, potentially your ability to work, potentially your ability to function. Seven months is what Canada produced with its universal healthcare system in 2025. Canada consistently ranks in the bottom tier of OECD countries for wait times despite spending 12 to 13% of GDP on healthcare, which is broadly comparable to Germany and Japan and Switzerland, all of which produce dramatically shorter waits. The money is going somewhere. It is not going to making treatment faster.

The United Kingdom’s National Health Service is a system that inspires genuine love and genuine despair in roughly equal proportions. In 2023, 61% of people in the UK reported waiting more than 4 weeks for a specialist appointment. That number was 14% in 2013. In one decade, a wait that affected one in seven people now affects three in five. 19% waited more than a year for non-emergency surgery. The NHS has 121,000 full-time equivalent staff vacancies. It has a 7.5% nursing vacancy rate. It has a dental crisis so severe that it is functionally creating a market for Turkish dentistry. The NHS was not always like this. The NHS spent decades being one of the more functional health systems on earth. The current situation is the result of specific policy decisions about funding, privatisation, outsourcing, and staffing that were made in the 1980s and 1990s and whose consequences are being harvested now.

Australia’s Medicare system is genuinely good by many measures, and the Australians are right to value it. The rural access problem is real and documented. The private insurance two-tier issue, where those who can afford private insurance access a faster and better-equipped system while those who cannot wait longer for public care, is a structural equity problem that has been growing since the Howard government’s incentive structures pushed people toward private insurance in 1997. The same incentive, applied at the same moment, by the same ideology, in multiple countries simultaneously. The English-speaking world had a shared political consensus in the 1990s about what healthcare should look like. That consensus has produced shared results. The results are not good.

New Zealand’s system has particular problems with primary care access. The general practitioner visit costs money in New Zealand in ways that it does not in Japan or Germany, which creates the same deterrence effect that the American system produces at scale, just at a lower level of severity. The deterrence means people do not see a doctor when a small problem is manageable. The small problem becomes a large one. The large one is addressed in an emergency department, which is expensive, which creates the same cost spiral that every system experiences when it prices primary care out of reach.

The English-speaking healthcare systems have a common problem that is distinct from the American problem and the Japanese solution. They built the architecture of universal care and then introduced market mechanics into the wrong parts of it. Fee structures, outsourcing, private participation incentives, workforce decisions driven by cost reduction rather than service capacity. The result is systems that are philosophically universal and operationally fragmented. They have the brand of Japan’s model without the discipline. They have the spend of America’s model without the innovation. They have produced a generation of patients who are technically covered and practically waiting.

Turkey. South Korea. The Countries That Saw a Gap and Built an Industry.

Here is the uncomfortable observation about medical tourism. It is not a story about adventurous individuals taking a calculated risk for a cheaper procedure. It is a story about the systematic failure of healthcare systems in wealthy countries creating demand that other countries are efficiently serving. Turkey did not build a 10 billion dollar health tourism industry by accident. It built it by correctly identifying that the UK could not provide timely dental care, that Canadians were waiting seven months for procedures, that Germans and Dutch and Scandinavians could access faster or cheaper options by flying four hours, and that people with money and a health problem and a long waiting list will spend that money somewhere. Turkey simply made itself that somewhere.

The numbers are striking. More than 1.2 million Europeans visited Turkey annually for surgical procedures as of 2024. Turkey’s health tourism revenue of 10 billion dollars in 2024 was generated at an average spend of 5,000 to 10,000 dollars per visitor. These are not budget travellers picking a destination on price alone. These are people with a medical need and the financial capacity to address it, who have calculated that flying to Istanbul and returning in a week is better than waiting seven months in their home country for a procedure that their home country is nominally obligated to provide.

South Korea has built a comparable industry but at the higher end of the quality spectrum. The K-beauty cultural phenomenon, which positioned Korean aesthetics and Korean medical standards as aspirational globally, has created a medical tourism market for cosmetic surgery and aesthetic medicine that attracts patients from China, Japan, Southeast Asia, the Middle East, and increasingly North America and Europe. South Korean clinics offer rhinoplasty, facial contouring, skin treatments, and complex aesthetic procedures with wait times measured in days and costs measured at 50 to 70% below comparable procedures in Western markets. Seoul’s Gangnam district has a higher density of plastic surgery clinics than any comparable area on earth. This is not incidental. It is a deliberately constructed industry responding to genuine global demand.

Malaysia has emerged as the preferred destination for Middle Eastern and South Asian patients who want Western-standard care at Asian prices, close to home, in a Muslim-majority country with English-speaking medical staff. Kuala Lumpur’s private hospital sector is accredited to international standards, priced at a fraction of Singapore or the Gulf’s premium facilities, and offers procedures from cardiac surgery to fertility treatment to oncology at price points that make flying there economically rational even for patients from wealthy countries. Malaysia’s medical tourism sector processed over a million patients in 2024 and continues to grow.

The logic is identical everywhere. A wealthy country’s healthcare system has a gap: in affordability, in access, in waiting time, in the specific procedure offered. Another country identifies the gap, builds the infrastructure to serve it, prices it appropriately, and captures the spend that the first country’s system was unwilling or unable to retain. This is how markets work. The irony is that the countries being bypassed are the ones that most loudly advocate for market solutions to healthcare problems. The market has spoken. The market says go to Istanbul.

The sequel cost is the part that the receiving healthcare systems prefer not to discuss. Bangor University research found that complications from medical tourism cost the NHS between 1,058 and 19,549 pounds per patient, with an average hospital stay for complications of 17 days, the longest being 45 days. The NHS is not only failing to provide timely dental care. It is paying to manage the consequences of that failure when the people it failed go abroad and return with complications. This is the structural logic of a system eating itself. The failure creates demand that goes elsewhere. The elsewhere creates complications. The complications come back. The complications cost more than the original failure would have cost to prevent.

The Philosophical Question That Is Also a Numbers Question.

The standard defence of the NHS, of Canadian Medicare, of Australian Medicare, of every struggling universal system, is that universal coverage is a moral achievement even if the execution is imperfect. This is true. Universal coverage is genuinely a moral achievement. The question worth asking is what universal coverage means when the waiting time for a specialist is seven months, when dental care is effectively inaccessible to a quarter of the population, when 19% of people wait more than a year for non-emergency surgery.

Japan covers 100% of its population. Singapore covers 100% of its population. Germany covers 100% of its population. Taiwan covers 100% of its population. These countries also have better outcomes, shorter wait times, lower costs per capita, and higher patient satisfaction than the English-speaking universal systems. The moral achievement of universal coverage does not require the operational failures that are being treated as inevitable consequences of providing that coverage. They are not inevitable. They are the result of specific decisions about funding, about pricing, about workforce, about the relationship between public and private provision, and about whether the system’s purpose is to serve patients or to serve the administrative and commercial interests that have grown up around patient care.

The United States is the clearest case of what happens when those commercial interests are given full authority. 18% of GDP. 69th globally in outcomes. A prior authorisation system where insurance companies employ physicians whose entire job is to deny the treatments that other physicians have prescribed. Pharmaceutical companies making 40% of their global revenue from 4% of the world’s population. A hospital consolidation process so advanced that private equity has created local monopolies in enough regions that patients have no alternative but to use the overpriced facility that has captured their geography. The US case is not a cautionary tale. It is the result of a deliberate and sustained policy of allowing commercial interests to dominate a market that does not behave like other markets because the consumer cannot shop around while dying.

The English-speaking universal systems are not the American system. But they have been moving toward it incrementally for thirty years. The outsourcing decisions. The private finance initiative contracts that locked public hospitals into expensive long-term arrangements with private providers. The two-tier incentive structures that pushed people toward private insurance. The workforce decisions that capped medical training places to protect income levels. The lobbying by various professional groups that turned healthcare administration into a growth industry while the number of actual clinicians relative to population fell. These are American decisions applied at a smaller scale. They produce American results at a smaller scale.

The countries that solved healthcare did not solve a medical problem. They solved a political economy problem. They decided who would be allowed to profit from illness, to what extent, and in what parts of the system. Japan and Singapore and Taiwan answered that question clearly and consistently. The English-speaking universal systems answered it less clearly, more inconsistently, in response to electoral cycles and industry lobbying rather than system design. The harvest is being eaten now. Seven months in Canada. Turkey teeth. Nineteen percent waiting a year for surgery. It is exactly what was planted.

What the Working Models Tell Us. And Why Nobody Copies Them.

There is a specific frustration in the global healthcare discussion, which is that the working models exist, have existed for decades, produce documented superior outcomes at comparable or lower cost, and are not copied. The reason they are not copied is not that they are too complex to replicate. Japan’s fee schedule model is well documented. Singapore’s 3M system is published. Germany’s regulated multi-payer model is publicly studied. The reason they are not copied is that copying them requires removing the profitability from the parts of the healthcare system that are currently most profitable, which are the parts that do not provide patient care.

The American private insurance industry generates several hundred billion dollars in annual revenue. A significant portion of this revenue is generated by the administrative machinery that exists between the patient and the physician: the prior authorisation system, the claims processing system, the appeals system, the legal system that defends denied claims, the consulting industry that advises on navigating the system. This machinery employs hundreds of thousands of people. It contributes to GDP. It lobbies Congress with approximately 750 million dollars per year to maintain the conditions that justify its existence. Removing it would require replacing it with something simpler, which would be better for patients and worse for the people currently employed to make the system complicated.

The NHS has a different but structurally analogous problem. The market mechanisms introduced into the NHS over thirty years have created internal markets, commissioning groups, procurement systems, outsourcing contracts, and quality monitoring frameworks that employ a large number of people who are not clinicians but whose existence depends on the NHS remaining complex enough to require their services. Simplifying the NHS would require acknowledging that complexity, and the employment it generates, is itself a cost with no patient care return. This is politically painful in a different way from the American political pain but produces the same result: the system that works for patients cannot be built because too many people are employed by the system that does not.

Japan avoided this by building the system before the administrative class had an opportunity to colonise it. Singapore avoided this by building the system with explicit constraints on what private profit could be extracted from it. South Korea avoided it through a combination of strong state architecture and a cultural consensus that healthcare outcomes mattered more than healthcare industry profits. The English-speaking countries built their systems in an era when these protections seemed unnecessary, watched the administrative class arrive and expand, and are now in the position of trying to remove it while it employs enough people to vote.

This is not a counsel of despair. It is a description of the mechanism. The mechanism can be changed. Simple antitrust enforcement in hospital consolidation. Transparent price-setting for common procedures. Workforce expansion to match population growth rather than to protect existing income levels. Primary care investment that reduces emergency department overload. These are not radical interventions. They are the normal maintenance of a system that stopped being maintained. The Japanese health ministry performs this maintenance continuously. The NHS maintenance budget was cut in the name of efficiency. The efficiency delivered 19% waiting more than a year for surgery and a medical tourism market worth 10 billion dollars in Turkey.

The final word belongs to the patient. Not the patient as a statistical unit in a healthcare quality index. The patient who checked their bank account before making the appointment. The Canadian who waited 28.6 weeks. The British person who flew to Istanbul for the teeth their NHS said could not see them for months. The Australian in a rural postcode whose nearest specialist is four hours away. The American who did not go to the doctor because the deductible was the rent. These people are not data points in a policy debate. They are the people the system was built for. The gap between what the system says it does and what it delivers to these specific people is where the cynicism earns its place. And where the accountability for the decisions of the 1990s should also live.

Article link: https://www.linkedin.com/pulse/global-healthcare-system-broken-japan-fixed-4100-per-person-alimov-n7xac?